Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed despite earlier trastuzumab-based therapy.

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ...

These studies led to Herceptin and Perjeta becoming standards of care and helped improve outcomes for people with early-stage HER2-positive breast cancer.3 About the APHINITY study APHINITY (Adjuvant ...

In the study, 270 patients with metastatic HR/HER2–positive breast cancer receiving a first to third line of treatment were randomized to one of two arms. In the chemotherapy arm, patients received ...

Herceptin has been the standard of care in the first line mBC since its first approval in 1998 as a monotherapy and later as a combination with Perjeta in 2012. It will be historic when it is no ...

Accord BioPharma announced that the FDA has approved Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor receptor 2 ...

Herceptin (trastuzumab) is one of these targeted medicines for breast cancer. It works against a protein called HER2 (also sometimes referred to as HER2/neu), which is short for human epidermal ...

Herceptin (trastuzumab) is a prescription drug that’s used to treat certain types of breast cancer and stomach cancer. Herceptin can cause side effects that range from mild to serious.

"This work attempts to understand why some HER2-positive breast cancer patients do not benefit from treatment with Herceptin, which is a generally effective HER2-targeted therapy," explains Bolin ...